In the intent-to-treat population, a
relative reduction of 19.7% in the combined
end point of death, MI, and stroke
was achieved by 28 days in those randomized
to a clopidogrel loading dose
(95% CI, −13.3% to 43.1%; P=.21). Although
the treatment effect from day
29 until the end of follow-up at 1 year
was not a prespecified analysis, continued
treatment with clopidogrel beyond
4 weeks was associated with a further
RRR of 37.4% in the combined end
point (95% CI, 1.8%-60.1%; P=.04).